SEC Form 4 · accession 0001209191-15-083423
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elaine Ullian
Director
Period of report
Dec 1, 2015
Accepted (ET)
Dec 3, 2015 · 9:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 1, 2015 | M | 22,500 | $59.55 | A | 27,765 | D | |
| Common StockF2,F3 | Dec 1, 2015 | S | 6,289 | $128.78 | D | 21,476 | D | |
| Common StockF3,F4 | Dec 1, 2015 | S | 10,711 | $129.77 | D | 10,765 | D | |
| Common StockF3,F5 | Dec 1, 2015 | S | 5,400 | $130.68 | D | 5,365 | D | |
| Common Stock | Dec 1, 2015 | S | 100 | $131.38 | D | 5,265 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $59.55 | Dec 1, 2015 | M | 22,500 | D | — | May 31, 2022 | Common Stock | 22,500 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $128.78 (range $128.25 to $129.23).
- F3Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $129.77 (range $129.25 to $130.24).
- F5Open market sales reported on this line occurred at a weighted average price of $130.68 (range $130.26 to $131.25).
- F6Fully vested.